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CLD = chronic lung disease; LRTI = lower respiratory tract infection; NANC(e) = nonadrenergic noncholinergic (excitatory component); NGF =
nerve growth factor; RAD = reactive airway disease; RSV = respiratory syncytial virus.
Available online http://respiratory-research.com/content/3/S1/S21
Introduction
Respiratory syncytial virus (RSV) is the most important
respiratory pathogen in infancy and can cause serious
lower respiratory tract infections (LRTIs), particularly in
prematurely born infants and children with underlying
cardiorespiratory conditions [1]. Epidemiologic studies
[2–9] have indicated that RSV LRTI in infancy is associ-
ated with recurrent wheezing later in life, giving rise to the
theory that there is a link between RSV and reactive
airway disease (RAD). The pathogenetic mechanisms of
RSV-induced airway inflammation and hyperreactivity
remain largely unknown, however, and no effective thera-
peutic option is currently available to manage the acute
and chronic clinical manifestations of this infection. The
present review focuses on the epidemiologic evidence
linking RSV and RAD, and on the cellular and molecular
mechanisms of airway inflammation during and after RSV
infection.
RSV LRTI: epidemiology and long-term
consequences
The majority of children will become infected with RSV by
the time they are 2 years old [10]. A link between RSV
LRTI in infancy and later development of RAD in childhood
has been suggested on the basis of several retrospective
studies (Table 1) [2–9]. In addition, two recent prospec-
tive studies [11,12], which are described below, have
confirmed that RSV is a major risk factor for the develop-
ment of recurrent wheezing and RAD during the first
decade of life.
Sigurs et al. [11] conducted a prospective study of 47 pre-
viously healthy infants hospitalized for RSV bronchiolitis
during their first year of life and a reference population of
93 infants with no history of RSV infection. The infants in
the two groups were well matched for age, sex, family
history of RAD or atopy, and general living environment.
There is substantial epidemiological evidence supporting the concept that respiratory syncytial virus
(RSV) lower respiratory tract infection in infancy may be linked to the development of reactive airway
disease (RAD) in childhood. However, much less is known concerning the mechanisms by which this
self-limiting infection leads to airway dysfunction that persists long after the virus is cleared from the
lungs. A better understanding of the RSV–RAD link may have important clinical implications,
particularly because prevention of RSV lower respiratory tract infection may reduce the occurrence of
RAD later in life. Among the mechanisms proposed to explain the chronic sequelae of RSV infection is
the interaction between the subepithelial neural network of the airway mucosa and the cellular
effectors of inflammatory and immune responses to the virus. The body of clinical literature linking RSV
and RAD is reviewed herein, as are the cellular and molecular mechanisms of neuroimmune
interactions and neural remodeling that may underlie this link, and the possibility that preventing the
infection may result in a decreased incidence of its chronic sequelae.
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RAD, wheezing, and recurrent wheezing were the outcome
measures. A diagnosis of RAD required having had three
or more episodes of physician-diagnosed bronchial
obstruction; recurrent wheezing was defined as three or
more episodes of self-reported bronchial obstruction; and
wheezing was defined as any episode of bronchial obstruc-
tion. The patient’s allergic status was determined with skin
prick testing and titers of serum IgE antibodies.
By 7 years of age 30% of children in the RSV group had
experienced RAD at some time, versus only 3% of children
in the reference group (Table 2) [11]. Likewise, 23% of
children in the RSV group had physician-diagnosed RAD
at age 7 years as compared with 2% of children in the ref-
erence group. The cumulative prevalence of wheezing
among children in the RSV group was twice that observed
in the reference group (68% versus 34%, respectively) and
the presence of any wheezing at age 7 years was 38% in
the RSV group and 2% in the control group. RSV bronchi-
olitis was the only significant risk factor for RAD, whereas
RSV bronchiolitis, family history of atopy, and male sex
were all risk factors for ‘any wheezing’. Multivariate analysis
showed that the highest frequency of RAD occurred when
both RSV bronchiolitis and a family history of atopy were
present as risk factors. That study also found a link
between RSV bronchiolitis and atopy; this has not been
observed in other studies, possibly due to differences in
the severity of RSV disease and/or genetic background
among the populations examined.
Stein  et al. [12] studied infants enrolled in the Tucson
Children’s Respiratory Study who developed mild to
severe RSV disease without necessarily requiring hospital-
ization. The study design required parents to complete
questionnaires when the children were 6, 8, 11, and
13 years old. A total of 472 out of 519 children who had
at least one LRTI during the first 3 years of life were tested
for viruses, and 207 of these 472 children had docu-
mented RSV infections. It was found that children with a
history of RSV LRTI were 3.2 times more likely to have
infrequent wheeze and 4.3 times more likely to have fre-
quent wheeze by age 6 years (Fig. 1). However, by the
time these children were 13 years old the association
between wheeze and RSV LRTI was no longer statistically
significant.
Another interesting finding was that, although children
who experienced RSV infection had significantly lower
forced expiratory volume in 1 s, they were also significantly
more responsive to bronchodilation with albuterol than
were the reference group [12]. This points to decreased
pulmonary function being caused by reversible dysregula-
tion of airway tone. Skin tests and serum IgE concentra-
tions showed no link between RSV infection and atopy.
Overall, the results of that study confirmed that when RSV
infection occurs in children by age 3 years it is linked to a
significantly increased risk for recurrent wheezing during
the first decade of life.
Cellular and molecular mechanisms linking
RSV to RAD
Various theories have been put forth in an attempt to
explain how RSV generates long-term airway inflammation
and hyperreactivity. We have proposed that interactions
between neural and immunoinflammatory mechanisms
may cause inflammation well after the initial RSV infection
is cleared. The discussion below addresses the interplay
between these mechanisms and how this may lead to
recurrent cycles of airway inflammation.
Neurogenic inflammation
An animal model of RSV bronchiolitis was developed in rat
strain Fischer F-344 [13]; these rats mount a strong
immune response and are thus able to clear RSV from the
lungs within few weeks. This is quite similar to the self-lim-
iting infection caused by RSV in immunocompetent chil-
dren. In addition, the inoculation of weanling rats with RSV
has allowed us to examine the long-term effects of early
RSV infection [14].
Table 1
Retrospective studies showing an association between
respiratory syncytial virus infection and reactive airway disease
Patients with  Years of  P
Reference Year RSV/total (n)* follow up (odds ratio)
[2] 1978 35/90 8 <0.02
[3] 1982 130/241 10 <0.001
[4] 1984 59/236 8 <0.0001
[5] 1984 100/300 7 <0.001
[6] 1987 51/75 2 <0.01
[7] 1992 73/146 5.5 <0.001
[8] 1993 70/140 1 0.001
[9] 1997 61/108 9–10 (3.59)
*The remainder of the patients were in the control group. RSV,
respiratory syncytial virus.
Table 2
Cumulative percentages of children with asthma, recurrent
wheezing, or any wheezing at age 7.5 years
RSV group  Control group 
Symptom (n = 47) (n = 93) P
Asthma 30% 3% <0.0001
Recurrent wheezing 28% 11% 0.015
Any wheezing 68% 34% <0.001
Data from Sigurs et al. [11]. RSV, respiratory syncytial virus.S23
Our first studies in this model focused on the nonadrener-
gic noncholinergic (NANC) nervous system and its role in
the modulation of local inflammatory and immune
responses in the airways. In particular, the excitatory com-
ponent of this NANC system (NANCe) is able to sense
the physical and chemical changes that arise in respiratory
epithelium exposed to airborne irritants, and sends to the
central nervous system the nociceptive information that
starts the cough reflex. In addition, NANCe nerves release
substance P and other peptide neurotransmitters at the
site of stimulation, playing an important role in the initial
phase of the inflammatory process and in the modulation
of the immune response to the virus.
We have found that RSV upregulates the expression of the
gene that encodes the NK1 receptor subtype, which medi-
ates the inflammatory and immunomodulatory effects of
substance P [13,14], thereby potentiating neurogenically
mediated airway inflammation. In contrast, RSV does not
affect the NK2 receptor subtype, which mediates airways
smooth muscle contraction, suggesting that airflow
obstruction during RSV infection is more likely to be due to
mucosal inflammatory edema than to bronchoconstriction.
In the animal model, developmental changes in the distrib-
ution of neurogenic inflammatory responses across the
respiratory tract were observed as the rats evolved from
infancy to adulthood; strong neurogenically mediated
inflammation developed in the lower respiratory tract of
young rats, whereas in adult rats this response was con-
fined to the large extrapulmonary airways. This observation
can be explained by a higher density and/or responsive-
ness of NANCe nerve fibers distributing to the lower
airways during infancy, and provides a potential mecha-
nism to explain why RSV bronchiolitis tends to occur
exclusively in infants, whereas infection with this virus
usually manifests as an upper respiratory tract infection in
older persons.
Lymphocytes
Our recent research has suggested that RSV infection
may also induce the expression of NK1 receptors in T-
lymphocyte subpopulations within the bronchiolar-associ-
ated lymphoid tissue. These NK1-receptor-bearing
lymphocytes are in essence ‘primed’ by the virus to be
deployed into the airways following nerve stimulation by
airborne irritants and can also be activated for the release
of proinflammatory cytokines. CD4+ T-helper cells appear
to be preferentially affected by the chemotactic activity of
substance P, which leads to accumulation of these cells in
the infected airways.
Mast cells
In a recent study [15] we showed that acute RSV infection
is associated with marked increase in the number of mast
cells in the airway mucosa. RSV also increased expression
of the 5-lipoxygenase gene, with transient production of
cysteinyl leukotrienes, probably deriving from the
expanded mast cell population found in infected lungs.
Interestingly, the mast cells in the infected mucosa
appeared to form clusters around nerve fibers, suggesting
functional interactions through the formation of local
neuron–mast cell feedback loops. In fact, the leukotriene
receptor antagonist montelukast potently inhibited neuro-
genically mediated inflammation in the intrapulmonary
airways of infected weanling rats, and to a much lesser
degree in adult rats. No significant inhibitory effect was
found in the extrapulmonary airways. These findings
suggest that leukotrienes are released via mast cell–nerve
interactions, which are amplified during RSV infections and
in turn potentiate the inflammatory effects of neuropeptides
such as substance P. If the same mechanisms are at work
in human airways then leukotriene modifiers could be bene-
ficial in the therapy of RSV bronchiolitis, and controller
therapy for pediatric asthma with leukotriene modifiers may
protect against virus-induced asthma exacerbations.
RSV-induced neural remodeling
Another recent study from our laboratory [16] showed that
aging is associated with a progressive decline in the
expression of the prototypical neurotrophin nerve growth
factor (NGF) in the lungs, which is paralleled by a similar
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Figure 1
Risk of frequent and infrequent wheeze in children who had mild to
moderate respiratory syncytial virus lower respiratory tract infection
[12]. CI, confidence interval; NS, not significant.S24
decline in the expression of its high-affinity (trkA) and low-
affinity (p75) receptors. RSV infection interferes with this
physiologic decline, promoting a large increase in the
expression of both NGF and neurotrophin receptors. The
lungs of weanling rats not only have markedly higher base-
line expression of neurotrophic factors but also appear to
be more responsive to the perturbation introduced by the
infecting virus. Furthermore, our data indicate that NGF
upregulates expression of the NK1 receptor, which medi-
ates the inflammatory effects of substance P and is
responsible for the exaggerated neurogenic inflammation
in RSV-infected airways. Accordingly, selective NGF
blockade inhibits neurogenically mediated inflammation
during RSV infection, and the magnitude of this inhibitory
effect is more prominent in younger animals. Thus, RSV-
induced release of NGF may lead to short-term and long-
term changes in the distribution and reactivity of sensory
nerves across the respiratory tract, contributing toward
exaggerated inflammatory reactions during and after the
infection. NGF and its receptors may also amplify other
immunoinflammatory and neuronal pathways that con-
tribute to airway inflammation and hyperreactivity. This
process of virus-dependent neural remodeling appears to
be particularly extensive when the infection occurs early in
life, because of the much higher degree of neural plasticity
that characterizes infancy.
In summary, we propose that remodeling of the sub-
mucosal neural network and the deriving cluster of neuro-
immune interactions may link RSV infections that occur
during critical developmental ‘windows’ with RAD in child-
hood. Based on this model, activation of the upregulated
NANCe system by irritants would be responsible for the
recurring airway inflammation and subsequent narrowing,
which continues after the acute RSV infection has cleared
(Fig. 2). If this is the case then it is possible that inhibition
of RSV penetration or replication in the lower respiratory
tract could reduce the frequency of childhood RAD.
Treating RSV
There are currently no effective treatments for acute RSV
infection, and there is little clinical evidence to indicate that
antiviral therapy will reduce the risk for developing RAD.
Results obtained with ribavirin were reviewed in order to
determine whether treatment helped to avoid long-term
sequelae [17]. In three controlled studies with long-term
follow up, no differences were observed between ribavirin-
treated and placebo-treated children with respect to the
incidence of long-term sequelae, RAD, recurrent LRTI, and
wheezing. The one study that reported a reduction in the
incidence of post-RSV RAD followed children for only
1 year, thus giving no real indication of whether antiviral
therapy has long-term beneficial effects in this regard.
Passive immunoprophylaxis is currently the only option for
avoiding RSV disease. IMpact-RSV [18] was a randomized,
double-blind, placebo-controlled trial conducted at 139
sites in the USA, the UK, and Canada. It evaluated prophy-
laxis with palivizumab, a humanized monoclonal antibody
that is specific for the RSV fusion protein, in 1502 prema-
turely born children with or without chronic lung disease
(CLD). Children received an intramuscular injection of
either palivizumab (15 mg/kg) or placebo every month for
5 months. An overall 55% reduction in hospitalizations for
RSV was observed as the primary endpoint of this study
(10.6% in the placebo group versus 4.8% in the
palivizumab group). Specifically, prematurely born children
without CLD had a 78% reduction in RSV-related hospi-
talizations (8.1% versus 1.8%) as compared with a 39%
reduction (12.8% versus 7.9%) for children with CLD.
These results, coupled with the epidemiologic evidence of
the link between RSV and RAD, raise the issue of whether
immunoprophylaxis against RSV can reduce the risk for
development of RAD. In our rat model, prophylaxis with
palivizumab prevented the development of acute neuro-
genic inflammatory changes in the lower respiratory tract
following inoculation of RSV [19]. Palivizumab prophylaxis
also appeared to guard against development of long-term
vulnerability to neurogenically mediated inflammation.
This issue was also approached in a study of children with
CLD (n = 13) who had received RSV immune globulin
7–10 years earlier [20]. Pulmonary function was signifi-
cantly better in the treatment group than in matched
control patients (P < 0.02). Significantly less atopy
(P = 0.04) and a lower likelihood of RAD attacks
(P = 0.03) were observed. Based on this preliminary
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Figure 2
Neuroinflammatory interactions and neural remodeling in airways
infected with respiratory syncytial virus. LTs, leukotrienes; NGF, nerve
growth factor; PMNs, polymorphonuclear leukocytes.S25
evidence, the investigators suggested that RSV prophy-
laxis might have long-term benefit in reducing the risk for
RAD.
Being 50–100 times more potent than RSV immune glob-
ulin, palivizumab may be an important alternative in the
prophylaxis of RSV and the avoidance of RAD. A prospec-
tive, multicenter, case–control study to examine the effect
of palivizumab prophylaxis on the incidence and degree of
reversible airway obstruction in premature children with
RSV is ongoing in Europe (Protocol W00-353; Abbott
Laboratories, Abbott Park, IL, USA). It is anticipated that
300 children will be enrolled and divided evenly between
three study arms; 100 children who receive palivizumab
prophylaxis will be compared with 100 children who had
documented RSV bronchiolitis and with 100 control chil-
dren. Follow up will continue for 3 years using monthly
telephone calls and scheduled visits at 6, 12, 24, and
36 months. The end-points include results from a respira-
tory questionnaire, history of wheezing, inventory of med-
ications used, record of hospitalizations, and
pharmacoeconomic evaluation. Results from the study are
anticipated at the end of 2003.
Conclusion
There is mounting evidence suggesting that young chil-
dren who contract RSV infection are more likely to suffer
from long-term respiratory sequelae, such as RAD, later in
life. This link has been supported by well controlled epi-
demiologic studies, and data from animal models have
identified molecular mechanisms that can explain the
effects of RSV infection on airway inflammation and hyper-
reactivity. Preventing RSV is therefore a promising
approach to reducing the incidence of RAD in childhood.
Studies evaluating the long-term benefits of RSV prophy-
laxis using agents such as palivizumab will help to deter-
mine the validity of this hypothesis.
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